Andere talen PepGen Inc.

Aandelen

PEPG

US7133171055

Beurs gesloten - Nasdaq Andere beurzen 22:30:00 03-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
14,2 ^USD	-2,00%		+19,03%	+108,82%

13/03	PepGen zegt dat potentiële behandeling voor Duchenne spierdystrofie door de FDA is aangewezen als weesgeneesmiddel en zeldzame pediatrische ziekte	MT
07/03	PEPGEN INC. : Wedbush herhaalt koopadvies	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

PepGen to Participate in Upcoming Investor Conferences	13/03
PepGen to Participate in Upcoming Investor Conferences	13/03
PepGen Says Potential Duchenne Muscular Dystrophy Treatment Gets FDA Orphan Drug, Rare Pediatric Disease Designations	13/03
PepGen's Rare Muscle Disorder Therapy Gets FDA Orphan Drug, Rare Pediatric Disease Designations	13/03
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	13/03
PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	13/03
PepGen Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	06/03
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	06/03
PepGen Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Developments	06/03
PepGen Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	06/03
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	04/03
PepGen Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	04/03
PepGen Inc. Announces Clearance of CTA by UK Medicines & Healthcare Products Regulatory Agency to Begin CONNECT2-EDO51, a Phase 2 Clinical Trial designed to support potential accelerated approval of PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy	04/03
PepGen Says FDA Grants Fast Track Designation to Potential Myotonic Dystrophy Type 1 Treatment	20/02
PepGen Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	20/02
PepGen Inc. Receives U.S. FDA Fast Track Designation for PGN-EDODM1 for the Treatment of Myotonic Dystrophy Type 1	20/02
PepGen Announces Pricing of $80.1 Million Underwritten Offering of Common Stock	07/02
Mary Beth DeLena Joins PepGen as General Counsel and Secretary	17/01
Mary Beth DeLena Joins PepGen as General Counsel and Secretary	17/01
PepGen Announces First Patient Dosed in CONNECT1-EDO51 Phase 2 Clinical Trial of PGN-EDO51 for Duchenne Muscular Dystrophy Patients Amenable to Exon 51 Skipping	08/01

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen PepGen Inc.

Aandelen

PEPG

US7133171055

Andere talen

Filters